PTX3 and neoplasm: There was a suggestion of efficacy that tumour shrinkage correlated with potential biomarkers such as CA19-9, Vitamin A levels, serum pentraxin 3 levels (PTX3) as well as tissue retinal binding proteins such as CRABP2 and FABP5 [17].